Lentivirally transduced autologous/allogeneic T cells expressing a CAR targeting CD20; IV infusion with dose escalation; designed for MHC-independent killing of CD20+ B-cell malignancies.
Autologous/allogeneic T cells are lentivirally engineered to express a CD20-specific chimeric antigen receptor. Binding to CD20 on malignant B cells triggers MHC-independent T-cell activation, proliferation, and cytotoxic killing via perforin/granzyme release and cytokine-mediated effects, leading to clearance of CD20+ cells.
CAR T cells bind CD20 on target cells, activate, and directly lyse them via perforin/granzyme release and death-receptor pathways (e.g., Fas/FasL), independent of MHC.
Polyclonal anti-T cell immunoglobulin used for T-lymphocyte depletion to reduce alloimmune responses.
Polyclonal anti–T‑cell immunoglobulin that binds multiple T‑lymphocyte surface antigens (e.g., CD2, CD3, CD4, CD8, CD25, HLA), triggering complement-dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis, resulting in rapid T‑cell depletion and suppression of alloimmune responses.
ATG binds CD8 alpha on T cells and induces complement-dependent lysis and Fc-mediated ADCC, and can trigger apoptosis, leading to depletion of CD8+ cells.
Polyclonal anti-T cell immunoglobulin used for T-lymphocyte depletion to reduce alloimmune responses.
Polyclonal anti–T‑cell immunoglobulin that binds multiple T‑lymphocyte surface antigens (e.g., CD2, CD3, CD4, CD8, CD25, HLA), triggering complement-dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis, resulting in rapid T‑cell depletion and suppression of alloimmune responses.
ATG antibodies bind CD25 on T cells and trigger complement-dependent cytotoxicity and Fc-mediated ADCC/phagocytosis, leading to lysis and apoptosis of the bound cells.
Polyclonal anti-T cell immunoglobulin used for T-lymphocyte depletion to reduce alloimmune responses.
Polyclonal anti–T‑cell immunoglobulin that binds multiple T‑lymphocyte surface antigens (e.g., CD2, CD3, CD4, CD8, CD25, HLA), triggering complement-dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis, resulting in rapid T‑cell depletion and suppression of alloimmune responses.
ATG antibodies bind HLA class I on T cells and trigger complement-dependent cytotoxicity and Fc-mediated ADCC, leading to apoptosis/lysis of the bound cells.
Polyclonal anti-T cell immunoglobulin used for T-lymphocyte depletion to reduce alloimmune responses.
Polyclonal anti–T‑cell immunoglobulin that binds multiple T‑lymphocyte surface antigens (e.g., CD2, CD3, CD4, CD8, CD25, HLA), triggering complement-dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, and apoptosis, resulting in rapid T‑cell depletion and suppression of alloimmune responses.
ATG contains antibodies that bind HLA antigens; binding to HLA-DR on the cell triggers complement-dependent lysis and Fc-mediated ADCC/apoptosis, depleting HLA-DR–positive cells.